Global Immune
Repertoire Sequencing Market, By Product Type (Assay Kits (T-Cell Receptor
Kits, and B-Cell Receptor Kits) and Instruments), By Application (Cancer
Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development
and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases, and
Other Applications), By End User (Diagnostic Labs, Biotechnology and
Pharmaceutical Companies, Academic and Research Institutes, and Others), and By
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) was valued at US$ 114.3 million
in 2017, and is projected to exhibit a CAGR of 5.6% over the forecast period
(2018 - 2026), as highlighted in a new report published by .
Increasing cancer research,
rising government support for pharmacogenomics based drug discovery, and rising
number of development programs in various therapeutic areas including oncology,
cardiology, infectious diseases, psychiatry, pain management, among others are
major factors expected to drive growth of the immune repertoire sequencing
market.
Moreover, various organizations
are focusing on developing new solutions to find personalized biomarkers in the
immune system for better and earlier diagnosis of a disease, eventually driving
growth of the immune repertoire sequencing market. For instance, in 2013, the
HudsonAlpha Institute for Biotechnology, U.S., initiated a project that aims to
sequence 10,000 individual’s T-cell repertoire on Illumina HiSeq and B-cell
repertoire on Roche’s 454 GS FLX for diagnosis of several diseases, including
cancers, autoimmune diseases, inflammatory diseases, and infectious diseases.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1517
Manufacturers in the immune
repertoire sequencing market are focusing on strategic mergers and acquisitions
in order to gain significant market share. For instance, in March 2018,
ArcherDX Inc. and Ambry Genetics entered into strategic partnership to provide
immune repertoire sequencing services to biopharmaceutical customers. This
partnership helped both companies to increase its product portfolio in immune
repertoire sequencing segment, globally. Similarly, in January 2018, Thermo
Fisher Scientific and Illumina, Inc. announced plan for partnership. This
agreement enables Illumina to sell Ion AmpliSeq technology to researchers who
conduct scientific studies on Illumina’s next-generation sequencing (NGS)
platforms.
Browse 38 Market Data Tables and
27 Figures spread through 200 Pages and in-depth TOC on "Immune Repertoire
Sequencing Market, By Product Type (Assay Kits {T-Cell Receptor Kits, and
B-Cell Receptor Kits}, and Instruments), By Application (Cancer Immunotherapy,
Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy,
Transplant Rejection and Tolerance, Infectious Diseases, and Other
Applications), By End User (Diagnostic Labs, Biotechnology and Pharmaceutical
Companies, Academic and Research Institutes, and Others), and By Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global
Forecast to 2026"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/immune-repertoire-sequencing-market-1517
Key Takeaways of the Immune
Repertoire Sequencing Market:
The global immune repertoire
sequencing market is expected to expand at a CAGR of 5.6% during the forecast
period (2018–2026), owing to increasing research & development and demand
for genomic and repertoire sequencing-based research.
Among product type, the assay kit
segment is expected to hold major revenue share in 2026. Various companies are
focusing on collaborations activities to develop immune repertoire
sequencing-based kits for certain immunotherapy response, which is expected to
drive growth of the assay kits segment in the market. For instance, in April
2018, MIODx and DiaCarta entered into an agreement for development of MIODx’s
ClonoMap immune repertoire sequencing-based tests, to predict patient response
to immunotherapy.
Major players operating in the
global immune repertoire sequencing market include Thermo Fisher Scientific,
Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD
Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies,
Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1517
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
